Technical aspects of urooncological interventions: third fall meeting of the European Society of Oncological Urology (ESOU), 13 - 15 January 2006, Brussels, Belgium
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
[Amsterdam u.a.]
Elsevier
2006
|
| Schriftenreihe: | European urology
Supplements ; 5,6 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | S. 471 - 536 Ill., graph. Darst. |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV021552351 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 060419s2006 ad|| |||| 10||| eng d | ||
| 035 | |a (OCoLC)75980822 | ||
| 035 | |a (DE-599)BVBBV021552351 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-19 | ||
| 245 | 1 | 0 | |a Technical aspects of urooncological interventions |b third fall meeting of the European Society of Oncological Urology (ESOU), 13 - 15 January 2006, Brussels, Belgium |c guest ed. Vincent Ravery |
| 264 | 1 | |a [Amsterdam u.a.] |b Elsevier |c 2006 | |
| 300 | |a S. 471 - 536 |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a European urology : Supplements |v 5,6 | |
| 650 | 4 | |a Urinary organs |x Cancer |x Treatment |v Congresses | |
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |2 gnd-content | |
| 700 | 1 | |a Ravery, Vincent |e Sonstige |4 oth | |
| 830 | 0 | |a European urology |v Supplements ; 5,6 |w (DE-604)BV016427937 |9 5,6 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014768402&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-014768402 | ||
Datensatz im Suchindex
| _version_ | 1804135309168869377 |
|---|---|
| adam_text | EUROPEAN UROLOGV SUPPLEMENTS, VOL. 5, NO. 6. APRIL 2006
CONTENTS
Editorial 471
V. Rovery
Current Role of PSA Kinetics in the Management of Patients with Prostate Cancer 472
L Klotz, S. Teohan
PSA kinetics (PSA Velocity and doubling time! can improve the management of patients in different
clinical situations: either to better diagnose prostate cancer, to monitor post treatment results or to
estimate the prognosis of the disease.
Active Surveillance with Selective Delayed Intervention for Favourable Risk Prostate Cancer: 479
Clinical Experience and a Number Needed to Treat Analysis
L Klotz, R. Nam
The proportion of all good risk patients, whatever the age, who die of disease (after surveillance and
delayed treatment] is not significantly different from the proportion dying in spite of aggressive
treatment, and watchful waiting is clearly appropriate in such patients, especially in the oldest ones.
External Radiotherapy and Prostate Cancer 487
P. Gastelblum, M. Roelandts, P. Van Houtte
External radiation therapy is very effective to treat localized prostate cancer, and even, in conjuction
with adjuvant hormone therapy, to treat more locally advanced disease, especially using a conformal
3 D technique.
Clinical Results of the Prostate HIFU Project 491
M. Colombel. L Poissonnier. X. Martin, A Gelet
The High Intensity Focused Ultrasound (HIFU) technique is effective to treat in a curative intent
patients with a low risk localized prostate cancer with an acceptable related morbidity.
PSA Isoforms in Prostate Cancer Detection 495
H. Ozen, S. Sozen
The diagnosis performance of total serum PSA is not optimal and may be improved by the use of its
isoforms, namely complexed PSA, free PSA, ( 2) proPSA and BPSA.
Prostate Biopsies and the Vienna Nomograms |EU ACME~j 500
8. Djavan
Traditional sextant biopsies might become obsolete in future designed trials since a body of evidence
supports the findings that this technique is far from optimal in patients with large prostates. In this
context, the Vienna nomogram offers an easy tool to select the optimal number of prostate biopsy
cores based on patient age and total prostate volume in PSA range 2 to 10 ng/ml.
Over and Underdiagnosis of Prostate Cancer: The Dangers 511
6. Tombai
The widespread use of PSA has led to a dramatic increase in the number of non clinically significant
prostate cancers for which an aggressive or even proactive treatment is more than questionable.
Interstitial Brachytherapy (LDR Brachytherapy) in the Treatment of Patients with Prostate lEU ACME I 514
Concer
S. Machtens, J.H. Karstens, R. Baumann, U. Jonas
More than 15 years experience with modern transperineal prostate brachytherapy has proven the
efficacy of this treatment approach in selected patients. However, treatment success rate, urinary
and rectal complications as well as preservation of sexual potency vary according to different
implant technical details.
EUROPEAN UROLOGY SUPPLEMENTS. VOL. 5. NO. 6. APRIL 2006
Organ Sparing Surgery for Testicular Lesions IEU ACME I 522
P. Alters
The organ sparing approach for testicular lesions represents the standard surgical approach to confirm
benign intratesticular disease. In solitary testes and malignant disease, this approach can be used in
presence of small tumour ( 2 cm, 30% of the testicular volume) and with normal pre operative
testosterone level. Moreover, patients should be treated at a centre with proven experience of this
rare clinical situation.
Risk Adapted Management of Clinical Stage I Nonseminomatous Testicular Germ Cell Tumours 525
A Heidenreich, C.H. Ohlmann
Despite evidence based available recommendations, management of clinical stage I nonseminomatous
germ cell tumours is still surrounded by controversy. However, all the treatment options including
surveillance, primary chemotherapy, and retroperitoneal lymph node dissection result in an overall
excellent treatment outcome with a 98% disease specific survival. Available risk factors can help to
identify an individualized risk adapted therapeutic.
Non Surgical Ablative Treatments for Small Renal Tumours Less Than 4 cm 533
P. Wkelan
Non surgical ablative approach, such as cryoablation and radiofrequency ablation, can be considered
as a valid treatment for small RCC l 4 cm) in selected patients. Encouraging evidences are now available
regarding safety and efficacy of this approach. However, future well designed trial are needed to assess
the long term oncological results of these non surgical treatments.
|
| adam_txt |
EUROPEAN UROLOGV SUPPLEMENTS, VOL. 5, NO. 6. APRIL 2006
CONTENTS
Editorial 471
V. Rovery
Current Role of PSA Kinetics in the Management of Patients with Prostate Cancer 472
L Klotz, S. Teohan
PSA kinetics (PSA Velocity and doubling time! can improve the management of patients in different
clinical situations: either to better diagnose prostate cancer, to monitor post treatment results or to
estimate the prognosis of the disease.
Active Surveillance with Selective Delayed Intervention for Favourable Risk Prostate Cancer: 479
Clinical Experience and a "Number Needed to Treat" Analysis
L Klotz, R. Nam
The proportion of all good risk patients, whatever the age, who die of disease (after surveillance and
delayed treatment] is not significantly different from the proportion dying in spite of aggressive
treatment, and watchful waiting is clearly appropriate in such patients, especially in the oldest ones.
External Radiotherapy and Prostate Cancer 487
P. Gastelblum, M. Roelandts, P. Van Houtte
External radiation therapy is very effective to treat localized prostate cancer, and even, in conjuction
with adjuvant hormone therapy, to treat more locally advanced disease, especially using a conformal
3 D technique.
Clinical Results of the Prostate HIFU Project 491
M. Colombel. L Poissonnier. X. Martin, A Gelet
The "High Intensity Focused Ultrasound" (HIFU) technique is effective to treat in a curative intent
patients with a low risk localized prostate cancer with an acceptable related morbidity.
PSA Isoforms in Prostate Cancer Detection 495
H. Ozen, S. Sozen
The diagnosis performance of total serum PSA is not optimal and may be improved by the use of its
isoforms, namely complexed PSA, free PSA, ( 2) proPSA and BPSA.
Prostate Biopsies and the Vienna Nomograms |EU ACME~j 500
8. Djavan
Traditional sextant biopsies might become obsolete in future designed trials since a body of evidence
supports the findings that this technique is far from optimal in patients with large prostates. In this
context, the Vienna nomogram offers an easy tool to select the optimal number of prostate biopsy
cores based on patient age and total prostate volume in PSA range 2 to 10 ng/ml.
Over and Underdiagnosis of Prostate Cancer: The Dangers 511
6. Tombai
The widespread use of PSA has led to a dramatic increase in the number of non clinically significant
prostate cancers for which an aggressive or even proactive treatment is more than questionable.
Interstitial Brachytherapy (LDR Brachytherapy) in the Treatment of Patients with Prostate lEU'ACME I 514
Concer
S. Machtens, J.H. Karstens, R. Baumann, U. Jonas
More than 15 years experience with modern transperineal prostate brachytherapy has proven the
efficacy of this treatment approach in selected patients. However, treatment success rate, urinary
and rectal complications as well as preservation of sexual potency vary according to different
implant technical details.
EUROPEAN UROLOGY SUPPLEMENTS. VOL. 5. NO. 6. APRIL 2006
Organ Sparing Surgery for Testicular Lesions IEU'ACME I 522
P. Alters
The organ sparing approach for testicular lesions represents the standard surgical approach to confirm
benign intratesticular disease. In solitary testes and malignant disease, this approach can be used in
presence of small tumour ( 2 cm, 30% of the testicular volume) and with normal pre operative
testosterone level. Moreover, patients should be treated at a centre with proven experience of this
rare clinical situation.
Risk Adapted Management of Clinical Stage I Nonseminomatous Testicular Germ Cell Tumours 525
A Heidenreich, C.H. Ohlmann
Despite evidence based available recommendations, management of clinical stage I nonseminomatous
germ cell tumours is still surrounded by controversy. However, all the treatment options including
surveillance, primary chemotherapy, and retroperitoneal lymph node dissection result in an overall
excellent treatment outcome with a 98% disease specific survival. Available risk factors can help to
identify an individualized risk adapted therapeutic.
Non Surgical Ablative Treatments for Small Renal Tumours Less Than 4 cm 533
P. Wkelan
Non surgical ablative approach, such as cryoablation and radiofrequency ablation, can be considered
as a valid treatment for small RCC l 4 cm) in selected patients. Encouraging evidences are now available
regarding safety and efficacy of this approach. However, future well designed trial are needed to assess
the long term oncological results of these non surgical treatments. |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| building | Verbundindex |
| bvnumber | BV021552351 |
| ctrlnum | (OCoLC)75980822 (DE-599)BVBBV021552351 |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01313nam a2200301 cb4500</leader><controlfield tag="001">BV021552351</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">060419s2006 ad|| |||| 10||| eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)75980822</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV021552351</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Technical aspects of urooncological interventions</subfield><subfield code="b">third fall meeting of the European Society of Oncological Urology (ESOU), 13 - 15 January 2006, Brussels, Belgium</subfield><subfield code="c">guest ed. Vincent Ravery</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">[Amsterdam u.a.]</subfield><subfield code="b">Elsevier</subfield><subfield code="c">2006</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">S. 471 - 536</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">European urology : Supplements</subfield><subfield code="v">5,6</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Urinary organs</subfield><subfield code="x">Cancer</subfield><subfield code="x">Treatment</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ravery, Vincent</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">European urology</subfield><subfield code="v">Supplements ; 5,6</subfield><subfield code="w">(DE-604)BV016427937</subfield><subfield code="9">5,6</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014768402&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-014768402</subfield></datafield></record></collection> |
| genre | (DE-588)1071861417 Konferenzschrift gnd-content |
| genre_facet | Konferenzschrift |
| id | DE-604.BV021552351 |
| illustrated | Illustrated |
| index_date | 2024-07-02T14:32:07Z |
| indexdate | 2024-07-09T20:38:27Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-014768402 |
| oclc_num | 75980822 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM |
| owner_facet | DE-19 DE-BY-UBM |
| physical | S. 471 - 536 Ill., graph. Darst. |
| publishDate | 2006 |
| publishDateSearch | 2006 |
| publishDateSort | 2006 |
| publisher | Elsevier |
| record_format | marc |
| series | European urology |
| series2 | European urology : Supplements |
| spelling | Technical aspects of urooncological interventions third fall meeting of the European Society of Oncological Urology (ESOU), 13 - 15 January 2006, Brussels, Belgium guest ed. Vincent Ravery [Amsterdam u.a.] Elsevier 2006 S. 471 - 536 Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier European urology : Supplements 5,6 Urinary organs Cancer Treatment Congresses (DE-588)1071861417 Konferenzschrift gnd-content Ravery, Vincent Sonstige oth European urology Supplements ; 5,6 (DE-604)BV016427937 5,6 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014768402&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Technical aspects of urooncological interventions third fall meeting of the European Society of Oncological Urology (ESOU), 13 - 15 January 2006, Brussels, Belgium European urology Urinary organs Cancer Treatment Congresses |
| subject_GND | (DE-588)1071861417 |
| title | Technical aspects of urooncological interventions third fall meeting of the European Society of Oncological Urology (ESOU), 13 - 15 January 2006, Brussels, Belgium |
| title_auth | Technical aspects of urooncological interventions third fall meeting of the European Society of Oncological Urology (ESOU), 13 - 15 January 2006, Brussels, Belgium |
| title_exact_search | Technical aspects of urooncological interventions third fall meeting of the European Society of Oncological Urology (ESOU), 13 - 15 January 2006, Brussels, Belgium |
| title_exact_search_txtP | Technical aspects of urooncological interventions third fall meeting of the European Society of Oncological Urology (ESOU), 13 - 15 January 2006, Brussels, Belgium |
| title_full | Technical aspects of urooncological interventions third fall meeting of the European Society of Oncological Urology (ESOU), 13 - 15 January 2006, Brussels, Belgium guest ed. Vincent Ravery |
| title_fullStr | Technical aspects of urooncological interventions third fall meeting of the European Society of Oncological Urology (ESOU), 13 - 15 January 2006, Brussels, Belgium guest ed. Vincent Ravery |
| title_full_unstemmed | Technical aspects of urooncological interventions third fall meeting of the European Society of Oncological Urology (ESOU), 13 - 15 January 2006, Brussels, Belgium guest ed. Vincent Ravery |
| title_short | Technical aspects of urooncological interventions |
| title_sort | technical aspects of urooncological interventions third fall meeting of the european society of oncological urology esou 13 15 january 2006 brussels belgium |
| title_sub | third fall meeting of the European Society of Oncological Urology (ESOU), 13 - 15 January 2006, Brussels, Belgium |
| topic | Urinary organs Cancer Treatment Congresses |
| topic_facet | Urinary organs Cancer Treatment Congresses Konferenzschrift |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014768402&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV016427937 |
| work_keys_str_mv | AT raveryvincent technicalaspectsofurooncologicalinterventionsthirdfallmeetingoftheeuropeansocietyofoncologicalurologyesou1315january2006brusselsbelgium |